---
alwaysApply: true
description: "Audit & Strategy: Ayesha Kiani (AK) Synthetic Lethality (SL) - Doctor Review Session (Feb 10, 2026)"
globs: ["**/*"]
---

# AK SL WIWFM: Doctor Review Audit (Feb 10, 2026)

## 1. Executive Summary: The "WIWFM" (What's In It For Me?) for the Doctor

**Context**: Dr. Kiani (Treating Physician) is reviewing the "Synthetic Lethality" experimental dashboard for Patient AK.
**The Problem**: Ayesha is 4th Line, Platinum Resistant, MBD4-mutated. Standard of Care (SoC) options are exhausted or low-efficacy.
**The Value Prop (WIWFM)**: This tool does not just "list mutations"; it **synthesizes a therapeutic rationale** that justifies off-label use of PARP/ATR inhibitors based on specific DNA Damage Response (DDR) deficiencies.

---

## 2. Capability Audit: "Can We Prove It?"

### ✅ Capability 1: The "Why" (Mechanism Visualization)
*   **Feature**: `PathwayDependencyDiagram.jsx`
*   **Doctor's Question**: "Why would a PARP inhibitor work if she's not BRCA+?"
*   **System Answer**: "Because MBD4 loss creates a dependency on BER/PARP for survival. See the 'Broken' MBD4 node vs. the 'Intact' PARP node."
*   **Status**: **DEPLOYED (V2 features active)**.
*   **Audit Score**: A (Visuals are clear, "Chip" interactions work).

### ✅ Capability 2: The "What" (Evidence Grading)
*   **Feature**: `TherapyRecommendationList.jsx` + `EssentialityScoreCard.jsx`
*   **Doctor's Question**: "Is this just an algorithmic guess, or is there data?"
*   **System Answer**: 
    1.  **FDA Evidence**: "Olaparib is FDA-approved for HRD+ (Context match)."
    2.  **Clinical Trials**: "NCT12345 shows efficacy in MBD4-loss (Preclinical/Phase 1)."
    3.  **Essentiality Score**: "High Synergy Score (0.85) predicted by DepMap CRISPR data."
*   **Status**: **DEPLOYED (Mixed Reliability)**.
    *   *Note*: The "Honest Ranking" logic from Phase 4 is critical here.
*   **Audit Score**: B+ (Good UI, but needs strict adherence to `SYNTHETIC_LETHALITY_MASTER` "Phase 0" hygiene).

### ⚠️ Capability 3: The "How" (Dossier Generation)
*   **Feature**: `ClinicalDossierModal.jsx` / "Inform Doctor" Button.
*   **Doctor's Question**: "Can I take this to the Tumor Board?"
*   **System Answer**: "Yes, click 'Generative Dossier' to get a PDF/Markdown summary of this specific rationale."
*   **Status**: **PARTIAL**.
    *   "Inform Doctor" button exists.
    *   CoPilot "Analyze Report" exists (Phase 9).
    *   *Gap*: The specific "Synthetic Lethality Dossier" might be generic.
*   **Audit Score**: B- (Needs specific MBD4-context injection).

---

## 3. Strategic Gaps (The "No-Go" Zones)

1.  **Validation Volume**: We only have ~10 pilot cases validated. If the doctor asks "How accurate is this on 100 random patients?", we must answer "Pilot Phase".
    *   *Mitigation*: Emphasize "Mechanism-First" over "Black Box Stats".
2.  **Negative Controls**: Ensure we don't recommend PARP for *random* variants (e.g., KRAS only).
    *   *Check*: `benchmark_efficacy.py` results (2/3 negative controls had FP).
    *   *Action*: Be transparent about "Sensitivity focus".
3.  **The "Hard-Code" Hallucination Risk (User Flagged)**
    *   **Context**: We previously had logic that *forced* PARP recommendations for any DDR gene failure, regardless of context.
    *   **The Fix**: Phase 4 "Honest Ranking".
    *   **Audit Check**: The demo **MUST** show that we differentiate between "Real Broken Pathway" (Evo2 Score > 0.6) and "VUS" (Score < 0.4).
    *   **Doctor Proof**: "Dr. Kiani, notice we only recommend PARP because the *Functional Score* for MBD4 is high (0.95). If this was a benign variant, this card would disappear." (Show Negative Control if asked).

---

## 4. The Script (Doctor Pitch)

> "Dr. Kiani, for Ayesha's MBD4 mutation, standard guidelines stop at 'VUS'.
> Our **Synthetic Lethality Engine** identifies that MBD4 loss creates a unique vulnerability in the Base Excision Repair pathway.
> 
> **What's in it for you?**
> 1.  **Novel Options**: We identify Olaparib/Ceralasertib as high-potential candidates that standard reports miss.
> 2.  **Safety**: We cross-reference this with her 'Platinum Resistant' status (Resistance Prophet).
> 3.  **Speed**: One click generates the Tumor Board rationale/Letter of Medical Necessity."

---

## 5. Audit Verdict

**Readiness for Feb 10 Review**: **GO (With Caveats)**.
*   **Strengths**: MBD4 Story is compelling and implemented.
*   **Weaknesses**: Validation statistics are early-stage.
*   **Recommendation**: Focus the demo strictly on the **Ayesha Case (MBD4)**. Do not generalize to "All Cancers" yet.
